• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sagimet Biosciences Inc.

    12/18/25 4:50:30 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Sagimet Biosciences Inc.

    (Name of Issuer)


    Series A Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    786700104

    (CUSIP Number)


    12/18/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    786700104


    1Names of Reporting Persons

    KPCB Pandemic and Bio Defense Fund, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The Reporting Person is making an early exit filing due to the planned termination and cancellation of the Reporting Person in Delaware before year-end.


    SCHEDULE 13G

    CUSIP No.
    786700104


    1Names of Reporting Persons

    KPCB PBD Associates, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The Reporting Person is making an early exit filing due to the planned termination and cancellation of the Reporting Person in Delaware before year-end.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sagimet Biosciences Inc.
    (b)Address of issuer's principal executive offices:

    Sagimet Biosciences Inc. 155 Bovet Road, Suite 303 San Mateo, CA, 94402
    Item 2. 
    (a)Name of person filing:

    This Schedule is filed by KPCB Pandemic and Bio Defense Fund, LLC, a Delaware limited liability company, and KPCB PBD Associates, LLC, a Delaware limited liability company. The foregoing entities are collectively referred to as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    c/o Kleiner Perkins Caufield & Byers, LLC, 2750 Sand Hill Road, Menlo Park, California 94025
    (c)Citizenship:

    See Row 4 of cover page for each Reporting Person.
    (d)Title of class of securities:

    Series A Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    786700104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited liability company agreements of the Reporting Persons, the members of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a member.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    KPCB Pandemic and Bio Defense Fund, LLC
     
    Signature:/s/ Susan Biglieri
    Name/Title:Susan Biglieri/Chief Financial Officer
    Date:12/17/2025
     
    KPCB PBD Associates, LLC
     
    Signature:/s/ Susan Biglieri
    Name/Title:Susan Biglieri/Chief Financial Officer
    Date:12/17/2025
    Get the next $SGMT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    8/11/2025$28.00Outperform
    Wedbush
    8/7/2025$29.00Buy
    H.C. Wainwright
    7/24/2025$28.00Buy
    Canaccord Genuity
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    More analyst ratings

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

    The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1 pharmacokinetic (PK) trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agoni

    12/18/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program

    License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet's fixed-dose combination (FDC) program currently in clinical developmentSagimet's Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagimet anticipates selecting one of the innovative forms of resmetirom licensed from TAPI for combination with denifanstat in a fixed dose combination (FDC) tablet for use in Phase 3 SAN MATEO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Bioscie

    12/17/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

    SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience Co. Ltd. (Ascletis), of which Ascletis Pharma Inc. is the parent company. Denifanstat is a once-daily oral small molecule fatty acid synthase (FA

    12/10/25 7:03:43 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sagimet Biosciences Inc.

    SCHEDULE 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    12/18/25 4:50:30 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    12/18/25 7:05:52 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    12/17/25 7:05:40 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Kemble George sold $289,979 worth of Series A Common Stock (37,688 units at $7.69), decreasing direct ownership by 32% to 81,005 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    11/21/25 6:13:11 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal & Admin. Officer Rozek Elizabeth was granted 9,855 units of Series A Common Stock, increasing direct ownership by 5% to 193,581 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    11/6/25 4:43:41 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Happel David sold $598,115 worth of Series A Common Stock (65,478 units at $9.13), decreasing direct ownership by 9% to 689,722 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:16:25 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    3/28/24 4:08:37 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Sagimet Biosciences with a new price target

    Wedbush initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $28.00

    8/11/25 10:06:29 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Sagimet Biosciences with a new price target

    H.C. Wainwright resumed coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $29.00

    8/7/25 7:42:15 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Sagimet Biosciences with a new price target

    Canaccord Genuity initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $28.00

    7/24/25 7:28:22 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Financials

    Live finance-specific insights

    View All

    Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

    8/14/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

    SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

    6/10/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Leadership Updates

    Live Leadership Updates

    View All

    Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

    SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

    5/6/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 4:31:38 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care